Immunotherapy—another breakthrough in gastrointestinal malignancies

被引：0
作者：
Monika Lenzi
Thomas Winder
机构：
[1] Landeskrankenhaus Feldkirch,Department of Internal Medicine II (Oncology, Hematology, Gastroenterology, Infectiology)
来源：
memo - Magazine of European Medical Oncology | 2022年 / 15卷
关键词：
Esophageal cancer; Gastric cancer; Hepatocellular cancer; Colorectal cancer; Gastrointestinal neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Immunotherapy is a breakthrough in different tumor entities. Recently, immunotherapy became an important treatment modality in gastrointestinal (GI) malignancies. In GI malignancies, immunotherapy with or without chemotherapy or targeted agents is revolutionizing the treatment landscape and our daily clinical practice. In this review, we discuss the relevance of immunotherapy in GI malignancies and provide a perspective on promising upcoming treatment strategies.
引用
收藏
页码：20 / 25
页数：5
相关论文
共 54 条
  • [1] de Ruiter EJ(2021)Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) Mod Pathol 34 1125-1132
  • [2] Mulder FJ(2017)Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Science 357 409-413
  • [3] Koomen BM(2020)Pembrolizumab plus chemotherapy vs chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase III KEYNOTE-590 study Ann Oncol 31 S1142-S1215
  • [4] Le DT(2021)Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the checkmate 648 study J Clin Oncol 39 LBA4001–LBA4001-1203
  • [5] Durham JN(2021)Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer N Engl J Med 384 1191-40
  • [6] Smith KN(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet 398 27-4002
  • [7] Kato K(2021)First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649 J Clin Oncol 39 4002-831
  • [8] Sun J(2020)First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial Lancet Oncol 21 821-3081
  • [9] Shah MA(2020)Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC) J Clin Oncol 38 3081-4013
  • [10] Chau I(2021)Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study J Clin Oncol 39 4013-1905
123456